Dr. John Crew Gives Grand Rounds Presentation on Treating Wounds With NovaBay's NeutroPhase at Eisenhower Medical Center
06 févr. 2014 08h30 HE | NovaBay Pharmaceuticals, Inc.
Dr. Crew Describes How His Breakthrough Treatment Using NeutroPhase is Saving the Lives and Limbs of Patients With Deadly 'Flesh-eating Disease' EMERYVILLE, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE)...
NovaBay Pharmaceuticals to Present at BIO CEO & Investor Conference
03 févr. 2014 08h30 HE | NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 3, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial...
Research Breakthrough for Deadly Flesh-Eating Disease Reported in the Journal Cell Highlights Importance of Neutralization of Toxins Associated With Flesh-Eating Bacteria
28 janv. 2014 08h30 HE | NovaBay Pharmaceuticals, Inc.
http://www.jpost.com/Health-and-Science/Hebrew-University-researchers-explain-how-innocent-bacteria-can-cause-flesh-eating-disease-338459 EMERYVILLE, Calif., Jan. 28, 2014 (GLOBE NEWSWIRE) --...
Mark Sieczkarek
Photo Release -- NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek, Solta Medical Chairman and CEO and Dr. Massimo Radaelli, Noventia Pharma CEO to Its Board of Directors
09 janv. 2014 08h30 HE | NovaBay Pharmaceuticals, Inc.
Combined Total of Over 50 Years of Healthcare Experience in Global Markets Adds Significant Depth to NovaBay's Board EMERYVILLE, Calif., Jan. 9 2014 (GLOBE NEWSWIRE) -- NovaBay®...
NovaBay Pharmaceuticals Provides Business Unit Update and 2014 Outlook
08 janv. 2014 08h30 HE | NovaBay Pharmaceuticals, Inc.
Urology Reported Positive Phase 2 Clinical Study Results of Auriclosene to Reduce Urinary Catheter Blockage and Encrustation (UCBE) Ophthalmology Completion of Global Conjunctivitis Clinical...
NovaBay Pharmaceuticals Announces Plan to Reinitiate Clinical Evaluation of Auriclosene for Impetigo in 2014
19 déc. 2013 08h00 HE | NovaBay Pharmaceuticals, Inc.
Impetigo Clinical Program Moves Forward With Optimized Formulation EMERYVILLE, Calif., Dec. 19, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage...
Dr. Ron Najafi, CEO of NovaBay Pharmaceuticals, Urges FDA to Formally Ban Antibiotic Use in Food Production
12 déc. 2013 08h30 HE | NovaBay Pharmaceuticals, Inc.
FDA's Recently Announced Plan to Curb Antibiotic Use in Animals is Merely Voluntary and Should go Further NovaBay Calls for Labeling of Antibiotic-fed Meats EMERYVILLE, Calif., Dec. 12, 2013...
NovaBay Pharmaceuticals Gains ISO 13485 Certification for the Design and Manufacturing of NeutroPhase(R)
11 déc. 2013 08h30 HE | NovaBay Pharmaceuticals, Inc.
Company Meets Internationally Recognized Quality and Regulatory Standards EMERYVILLE, Calif., Dec. 11, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage...
NovaBay Pharmaceuticals and China Pioneer Pharma Announce Expansion of Partnership Agreement
02 déc. 2013 09h02 HE | NovaBay Pharmaceuticals, Inc.
Pioneer to License Rights to Commercialize Two New NovaBay Products In China and Southeast Asia NovaBay to Receive $5.7 Million Equity Investment from China Pioneer Pharma EMERYVILLE, Calif.,...
NovaBay Pharmaceuticals Reports Third Quarter 2013 Financial Results and a Clinical/Business Update
14 nov. 2013 09h20 HE | NovaBay Pharmaceuticals, Inc.
Phase 2b study of Auriclosene for Impetigo Completed by Partner Galderma Reported Positive Results from Phase 2 Clinical Study of Auriclosene to Reduce Urinary Catheter Blockage and Encrustation...